FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1607-1608 June 13, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mandel, J. S. Related Article by Allison, J. E. PubMed Citation

To the Editor: My colleagues and I reported (Jan. 18 issue) that HemeSelect and a combination test in which HemeSelect is used to confirm positive Hemoccult II Sensa results are an improvement over Hemoccult II in screening patients for colorectal carcinoma.¹ In their accompanying editorial, Ransohoff and Lang² limited their endorsement of the combination test, because they misinterpreted our methods and did not recognize that our study was conducted in a setting of routine patient care, not in a clinical-trial setting. Fecal occult-blood testing has been a part of the Kaiser Permanente personal- health appraisal since the late 1970s.

We . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.